0.571

4.83% -0.029

Traws Pharma Inc (TRAW)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$0.60

Offen:

$0.607

24-Stunden-Volumen:

75,274

Relative Volume:

0.18

Marktkapitalisierung:

$8.70M

Einnahmen:

$2.73M

Nettoeinkommen (Verlust:

$-19.43M

KGV:

-0.2511

EPS:

-2.2739

Netto-Cashflow:

$-17.91M

1W Leistung:

+7.33%

1M Leistung:

-18.98%

6M Leistung:

-70.26%

1J Leistung:

-64.75%

1-Tages-Spanne:

$0.57

$0.6165

1-Wochen-Bereich:

$0.53

$0.6165

52-Wochen-Spanne:

$0.4301

$3.265

Traws Pharma Inc Stock (TRAW) Company Profile

Firmenname

Traws Pharma Inc

Sektor

Healthcare (1080)

Branche

Biotechnology (604)

Telefon

267-759-3680

Adresse

12 PENNS TRAIL, NEWTOWN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

TRAW's Discussions on Twitter

Compare TRAW vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TRAW Traws Pharma Inc	0.571	8.12M	2.73M	-19.43M	-17.91M	-2.2739
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-03	Eingeleitet	H.C. Wainwright	Buy
2022-03-01	Eingeleitet	Ladenburg Thalmann	Buy
2021-05-18	Eingeleitet	Guggenheim	Buy
2018-03-01	Bestätigt	H.C. Wainwright	Buy
2018-01-17	Herabstufung	Maxim Group	Buy → Hold
2017-10-09	Eingeleitet	H.C. Wainwright	Buy
2017-04-27	Eingeleitet	Laidlaw	Buy
2015-07-01	Hochstufung	Piper Jaffray	Neutral → Overweight
2015-05-05	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Traws Pharma Inc Aktie (TRAW) Neueste Nachrichten

Aug 14, 2026

Ikarian Capital (TRAW) reports 1.56M-share, 9.5% beneficial stake in Traws Pharma - Stock Titan

Aug 14, 2026

Traws Pharma Flags Cash Runway Risk Into Q1 2027 Amid FDA Clinical Hold - Minichart

Aug 14, 2026

Traws Pharma Reports Q2 Results, Influenza Program Advances - TipRanks

Aug 14, 2026

Traws Pharma Q2 Results: EPS beats estimate, losses widen 45% YoY - scanx.trade

Aug 14, 2026

Traws Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times

Aug 14, 2026

Traws Pharma Q2 revenue falls to zero on licensing termination; net loss widens - TradingView

Aug 14, 2026

Traws Pharma Reports Q2 2026 Net Loss of $3.0 Million - Quiver Quantitative

Aug 14, 2026

Traws Pharma Expects Q3 Resubmission for Flu Antiviral - Stock Titan

Aug 14, 2026

Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A - Stock Titan

Aug 14, 2026

Sirenia Capital (TRAW) discloses warrant-based stake capped at 9.9% ownership - Stock Titan

Aug 14, 2026

Aug 13, 2026

Traws Pharma Inc (NASDAQ: TRAW) Share Price, TRAW Stock News, TRAW Share Price & Updates - Kalkine

Aug 13, 2026

Aug 12, 2026

Adage Capital reports 4.79% Traws Pharma (TRAW) stake totaling 730,000 shares - Stock Titan

Aug 12, 2026

Aug 10, 2026

Why Did TRAW Stock Slump 28% After Hours? - Stocktwits

Aug 10, 2026

Traws Pharma Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 09, 2026